scholarly journals Sphingosine kinase 2 plays a critical role in bile acid‐induced cholestatic liver injury via regulating miR‐155 and macrophage activation

2020 ◽  
Vol 34 (S1) ◽  
pp. 1-1
Author(s):  
Yuan Zhang ◽  
Wilson Yang ◽  
Yanyan Wang ◽  
Runping Liu ◽  
Xiaojiaoyang Li ◽  
...  
2020 ◽  
Vol 158 (6) ◽  
pp. S-1277
Author(s):  
Jilin Wu ◽  
Yanyan Wang ◽  
Pu Ge ◽  
Yunling Tai ◽  
Yuan Zhang ◽  
...  

2018 ◽  
Vol 19 (9) ◽  
pp. 2509 ◽  
Author(s):  
Jing Zhang ◽  
Xin Guo ◽  
Taiji Hamada ◽  
Seiya Yokoyama ◽  
Yuka Nakamura ◽  
...  

Accumulating evidence indicates that oxidative stress plays a critical role in initiating the progression of inflammatory and fibrotic liver diseases, including cholestatic hepatitis. Peroxiredoxin 4 (PRDX4) is a secretory antioxidase that protects against oxidative damage by scavenging reactive oxygen species (ROS) in both the intracellular compartments and extracellular space. In this study, we examined the in vivo net effects of PRDX4 overexpression in a murine model of cholestasis. To induce cholestatic liver injury, we subjected C57BL/6J wild-type (WT) or human PRDX4 (hPRDX4) transgenic (Tg) mice to sham or bile duct ligation (BDL) surgery for seven days. Our results showed that the liver necrosis area was significantly suppressed in Tg BDL mice with a reduction in the severity of liver injuries. Furthermore, PRDX4 overexpression markedly reduced local and systemic oxidative stress generated by BDL. In addition, suppression of inflammatory cell infiltration, reduced proliferation of hepatocytes and intrahepatic bile ducts, and less fibrosis were also found in the liver of Tg BDL mice, along with a reduced mortality rate after BDL surgery. Interestingly, the composition of the hepatic bile acids (BAs) was more beneficial for Tg BDL mice than for WT BDL mice, suggesting that PRDX4 overexpression may affect BA metabolism during cholestasis. These features indicate that PRDX4 plays an important role in protecting against liver injury following BDL and might be a promising therapeutic modality for cholestatic diseases.


2017 ◽  
Vol 161 (1) ◽  
pp. 34-47 ◽  
Author(s):  
Jibiao Li ◽  
Benjamin L Woolbright ◽  
Wen Zhao ◽  
Yifeng Wang ◽  
David Matye ◽  
...  

2020 ◽  
Vol 158 (6) ◽  
pp. S-1352
Author(s):  
Haiyue He ◽  
Yanliang Hou ◽  
Zichun Li ◽  
Xiaomei Zhang ◽  
Xiaowei Liu

2021 ◽  
Author(s):  
Yangping Zhu ◽  
Changling Wang ◽  
Jingyi Yu ◽  
Yingying Miao ◽  
Yuanyuan Chai ◽  
...  

Abstract Background: Lithocholic acid (LCA) is one kind of endogenous bile acids which is a typical index in primary biliary cholangitis (PBC). It could cause severe cholestatic liver injury in rodents. Obeticholic acid (OCA) is a major treatment for PBC. However, its effect and mechanism in LCA-induced liver injury was still unclear beside of bile acid regulation. This study aims to evaluate the hepatoprotective effect and mechanism of OCA against LCA-induced cholestatic liver injury. Results: LCA-induced upregulations of ALT, AST, ALP and TBA were reduced and the bile acid profiles in serum, liver and bile were improved significantly by OCA. This bile acid regulating effect of OCA was mainly based on increasing the expression of bile acid efflux transporters bile salt export pump (BSEP), multidrug resistant associated protein 2 (MRP2), MRP3 and multi-drug resistance 3 (MDR3) instead of bile acid synthesis inhibition. Furthermore, it was found that OCA reduced the activation and expression of Caspase 8/3 signaling pathway without the change of p-MLKL and BAX in LCA-induced cholestatic model. And the inhibition of Caspase 8/3 signaling pathway depended on the activation of Farnesoid X receptor (FXR) to inhibit Caspase 8 cleavage to form a active complex.Conclusions: This study found OCA improved LCA-induced cholestatic liver injury via FXR-induced exogenous cell apoptosis, which provided a new evidence for the application of OCA to ameliorate PBC in clinical.


Sign in / Sign up

Export Citation Format

Share Document